Background The efficacy and safety of bivalirudin versus heparin in patients undergoing
percutaneous coronary intervention (PCI) 1 remains controversial in to date. Our meta …

Background: This meta-analysis is to evaluate the efficacy and safety of bivalirudin in
patients with ST-elevation myocardial infarction (STEMI). Methods: PubMed, Cochrane …

Aims Given controversy over anticoagulation regimens for percutaneous coronary
intervention (PCI), we performed an updated meta-analysis of randomized controlled trials …

Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa
inhibitors has been shown to be as effective as unfractionated heparin plus routine …

Background Bivalirudin has been shown to be associated with less major bleeding than
heparin in patients undergoing percutaneous coronary intervention (PCI); but the …

Aims: Current recommendations on the use of bivalirudin in patients treated with
percutaneous coronary intervention (PCI) are mostly based on trials comparing bivalirudin …

Background Bivalirudin is an alternative to heparin in patients undergoing percutaneous
coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based …

Recent clinical trials have shown that while bivalirudin exhibits similar efficacy with heparin,
it offers several advantages over heparin, such as a better safety profile. We aimed to …

The results of randomized trials and observational studies make a strong argument for the
use of bivalirudin rather than heparin plus systematic glycoprotein (GP) IIb/IIIa inhibitors for …

Background: Although the current practice guidelines recommend using both heparin and
bivalirudin for percutaneous coronary interventions (PCI), the research data are ambiguous …